Trial: 202012015

A Phase II, Randomized, Double Blind Study of Atezolizumab plus Tiragolumab and Atezolizumab plus placebo as First Line Treatment in Patients with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck


II (Cancer Control)

Principal Investigator

Adkins, Douglas

Disease Site

Larynx; Lip, Oral Cavity and Pharynx

Learn more about this study at: